Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31578986 | 0.91 | TSHR (0.74) | TSHRLMNAALDH1A1KDM4ERECQL | |
| SCHEMBL18528321 | 0.89 | TSHR (0.58) | TSHRLMNAALDH1A1KDM4ERECQL | |
| SCHEMBL6053220 | 0.89 | TSHR (0.58) | TSHRLMNAALDH1A1KDM4ERECQL | |
| SCHEMBL11313358 | 0.88 | TSHR (0.70) | TSHRLMNAALDH1A1KDM4ERECQL | |
| SCHEMBL31578856 | 0.88 | TSHR (0.70) | TSHRLMNAALDH1A1KDM4ERECQL | |
| SCHEMBL31579008 | 0.88 | TSHR (0.70) | TSHRLMNAALDH1A1KDM4ERECQL | |
| SCHEMBL31578944 | 0.88 | TSHR (0.70) | TSHRLMNAALDH1A1KDM4ERECQL | |
| SCHEMBL29209613 | 0.86 | TSHR (0.65) | TSHRLMNAALDH1A1KDM4ERECQL | |
| SCHEMBL8038535 | 0.86 | TSHR (0.67) | TSHRLMNAALDH1A1KDM4ERECQL | |
| SCHEMBL13224279 | 0.86 | TSHR (0.67) | TSHRLMNAALDH1A1KDM4ERECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6965029-B2 | Method for producing enantiomer-free 6,8 dihydroxy octanoic acid esters by means of asymmetric, catalytic hydrogenation | VIATRIS GMBH & CO. KG (DE) | 2005-11-15 | — | — | US | disclosed |
| EP-1303475-B1 | METHOD FOR PRODUCING ENANTIOMER-FREE 6,8 DIHYDROXY OCTANOIC ACID ESTERS BY MEANS OF ASYMMETRIC, CATALYTIC HYDROGENATION | VIATRIS GMBH (DE) | 2005-06-08 | — | — | EP | disclosed |
| US-20040030178-A1 | Method for producing enantiomer-free 6,8 dihydroxy octanoic acid esters by means of asymmetric, catalytic hydrogenation | VIATRIS GMBH & CO. KG (DE) | 2004-02-12 | — | — | US | disclosed |
| EP-1303475-A1 | METHOD FOR PRODUCING ENANTIOMER-FREE 6,8 DIHYDROXY OCTANOIC ACID ESTERS BY MEANS OF ASYMMETRIC, CATALYTIC HYDROGENATION | VIATRIS GmbH & Co. KG (DE) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002010113-A1 | METHOD FOR PRODUCING ENANTIOMER-FREE 6,8 DIHYDROXY OCTANOIC ACID ESTERS BY MEANS OF ASYMMETRIC, CATALYTIC HYDROGENATION | VIATRIS GMBH & CO. KG (DE) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040030178-A1 | Method for producing enantiomer-free 6,8 dihydroxy octanoic acid esters by means of asymmetric, catalytic hydrogenation | ACSL6, HACL2, CYP8B1 | TSHR 3479/4885LMNA 2721/4885ALDH1A1 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.